Patent · US Active

Method for the production of human immunodeficiency virus (HIV) proteins utilizing modified vaccinia virus ankara (MVA) recombinants comprising HIV genes inserted into one or more intergenic regions (IGRs)

US8197822B2 · kind B2 · utility

3Cited by

10References

19Claims

0Family size

Assignee

Bavarian Nordic A/S · DK

Inventors

Paul Howley · Scone, AU
Sonja Leyrer · Munich, DE
Paul Chaplin · Munich, DE
Eva Felder · Munich, DE

Key dates

Filing date	Aug 15, 2011
Grant date	Jun 12, 2012
Priority date	—
Expiry date	Aug 15, 2031

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to novel insertion sites useful for the integration of HIV DNA sequences into the MVA genome, and to the resulting recombinant MVA derivatives.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.